Should You Get the New Alzheimer's Blood Test If Your Cognitive Screening Came Back Normal?

You sat down with your doctor, answered the questions, drew the clock, repeated the words. The cognitive screening came back normal. Your doctor smiled, said everything looked fine, and sent you on your way.

And yet here you are, still wondering. Because your mother has Alzheimer's. Or your father did. Or both. And "normal for now" does not feel like nearly enough of an answer.

That instinct is not anxiety. It is actually good science.

A new generation of blood tests is changing what we can know about Alzheimer's risk long before any cognitive screening would ever catch it. If you have a family history, if you carry a gene like APOE4, or if you simply want to understand what is happening inside your brain now, these tests deserve a serious conversation with your clinician. Let me explain what they are, what they can and cannot tell you, and how to think about whether one makes sense for you.

What a "Normal" Cognitive Screening Actually Measures

Cognitive screenings like the MoCA (Montreal Cognitive Assessment) are useful tools. They measure what your brain is doing right now: attention, short-term recall, language, visuospatial function. If you score well, it means those systems are working well today.

What a cognitive screening cannot do is look upstream. It cannot tell you whether the biological changes associated with Alzheimer's are already underway in your brain. And here is the part that matters: those biological changes typically begin 15 to 20 years before any memory or thinking symptom appears.

By the time a cognitive test catches something, a long process has already been running quietly in the background.

This is precisely why "watchful waiting", the standard approach of screening periodically and acting only when decline shows up, is an outdated strategy for anyone who wants to be proactive about their brain health. It is like checking your blood pressure only after you have had a stroke.

What the New Blood Tests Are Actually Measuring

The test generating the most rigorous attention right now measures something called p-tau217 (phosphorylated tau 217). Tau is a protein that, when abnormally modified, forms the "tangles" that are one of the hallmarks of Alzheimer's disease in the brain. Elevated p-tau217 in the blood is strongly associated with the presence of amyloid plaques and tau pathology in the brain, often many years before symptoms emerge.

Tests like PrecivityAD2 use p-tau217 alongside other biomarkers to produce a result that correlates closely with what PET scans (specialized brain imaging) and spinal fluid tests have traditionally shown. Those older methods are accurate but expensive, invasive, and not widely accessible. A blood draw is a different proposition entirely.

To be direct about what these tests are and are not: a positive result does not mean you will definitely develop dementia. A negative result does not guarantee you will not. What these tests do is clarify biological risk at a level that no cognitive screening can reach. They move the conversation from "how is your brain performing today" to "what is your brain's trajectory, and what can we do about it."

That is a fundamentally more useful question to be asking in your 50s or 60s.

Who Should Seriously Consider Getting Tested

The Alzheimer's Association has issued updated guidance on blood biomarker testing, and the clinical conversation is evolving quickly. In my practice, the people I think most benefit from this kind of testing fall into a few overlapping groups.

• Family history of Alzheimer's or dementia. One affected parent meaningfully raises your risk. Two affected parents, or multiple relatives across generations, raises it further. If this is your situation, "your screening was normal" is a starting point, not a destination.
• Known APOE4 carriers. APOE4 is the most common genetic risk factor for late-onset Alzheimer's. Carrying one copy raises risk; carrying two copies raises it substantially more. If you know you carry this variant, understanding your biomarker status gives you actionable information.
• Subtle subjective changes. You scored fine on the test, but you notice something, word retrieval that feels slower, a new reliance on lists, a mental fogginess that was not there five years ago. Subjective cognitive concern in someone with a normal screening is exactly the situation where biomarker testing adds the most clarity.
• People who want to act early and systematically. Some of my patients simply want the full picture. They are managing their cardiovascular health, their metabolic health, their sleep, their stress. Adding brain biomarker data to that picture is consistent with how they approach everything else. This is a legitimate reason.

If none of these apply to you and your screening was normal, the conversation is different. But if even one of them fits, this test is worth discussing with a clinician who understands how to interpret it in context.

The Result Is Information, Not a Verdict

This is the part I want to be very clear about, because it is where people understandably get stuck.

A blood biomarker result, positive or negative, is one data point. It is a meaningful data point. But it does not determine your future. What it does is help you and your care team understand where you are on a biological continuum, and therefore what to prioritize.

If your p-tau217 result is elevated, that is not a diagnosis. It is a signal that the biological environment in your brain warrants a closer look and a more aggressive optimization of every modifiable health factor we know matters: sleep quality, cardiovascular fitness, metabolic health, inflammation, hormonal balance, stress physiology, nutritional status. These are not peripheral to brain health. They are central to it.

Acting on that signal early, while your cognitive function is still fully intact, is exactly when intervention has the greatest potential to move the needle.

If your result is reassuring, that is genuinely useful information too. It helps contextualize your risk, guide monitoring frequency, and inform which health investments make the most sense for you specifically.

Either way, you are not more informed by not knowing.

A Word on Testing Outside a Clinical Context

Direct-to-consumer options are appearing, and patients are increasingly finding ways to order these tests without a physician's involvement. I understand the impulse. You want answers, and sometimes the medical system makes it harder than it should be to get them.

My honest advice: do not interpret these results alone. The accuracy of p-tau217 tests is genuinely high, but no blood test exists in a vacuum. The result needs to be read alongside your full clinical picture: your history, your other health data, your risk factors, your goals. A positive result without proper context can cause unnecessary distress. A negative result without proper context can create false reassurance.

Find a clinician who takes proactive brain health seriously and will work through the results with you. That conversation is part of the value.

What Early Action Actually Looks Like

In my work, I have seen what happens when people get this information early and use it well. One patient, Susan, came to me with early memory concerns and a strong family history. Rather than watch and wait, we took a root-cause approach, identified and addressed the underlying health stressors contributing to her symptoms, and her memory function improved. She has maintained that improvement for over a decade. I am not telling you her outcome is guaranteed for anyone else. I am telling you it is possible when you act early, broadly, and systematically.

The specific steps look different for each person, because a whole-person, precision approach means your biology, your history, and your goals shape the plan. But the categories of action are consistent:

1. Understand your biomarker status and genetic risk so you know what you are actually working with.
2. Identify and address the modifiable health stressors that are driving biological aging in your brain.
3. Optimize the fundamentals: sleep, movement, metabolic health, inflammation, stress, social and cognitive engagement.
4. Monitor with the right metrics over time, not just periodic cognitive screenings.

The years before decline declares itself are the most important years to be doing this work. That is not a reason for alarm. It is a reason for action.

The Bottom Line

A normal cognitive screening is good news. It is not the whole story.

If you have family history, genetic risk, or even a quiet sense that something has shifted, a blood biomarker test like p-tau217 can give you information that no cognitive screening can. That information, interpreted carefully with a knowledgeable clinician, can help you make smarter decisions about your brain health right now, while the window for meaningful action is wide open.

Brain aging does not have to mean decline. But that outcome does not happen by waiting to see what happens. It happens because you decided to find out, and then decided to act.

This post is for educational purposes only and is not a substitute for personalized medical advice. Please consult a qualified clinician before ordering or interpreting any diagnostic test.

Frequently Asked Questions

How accurate is the p-tau217 blood test compared to a PET scan or spinal fluid test?

Studies have shown that p-tau217 blood tests correlate strongly with amyloid PET imaging and cerebrospinal fluid biomarkers, which have long been the gold standard for detecting Alzheimer's-related brain changes. Accuracy figures in recent research have been consistently high, though no blood test is perfect. False positives and false negatives do occur, which is exactly why results should be interpreted by a clinician who can weigh them alongside your full clinical picture, not in isolation.

My cognitive screening was completely normal. Does that mean a blood test would just cause unnecessary worry?

Not necessarily. The concern about "unnecessary worry" is real, and it is worth taking seriously. But uninformed worry is not the same as informed action. If your result comes back reassuring, you have meaningful data supporting your current trajectory. If it comes back elevated, you have a chance to act during the window when intervention matters most. The goal is not to generate anxiety; it is to replace uncertainty with information you can actually use. That said, this is a genuinely personal decision, and it is worth thinking through with a clinician who understands both the science and your specific situation.

Who should order this test, and can I get it without a doctor's referral?

Some direct-to-consumer options exist, but I would encourage you to go through a clinician if at all possible. The test is most useful when it is part of a broader clinical conversation: your family history, your other health data, your risk profile, and what you plan to do with the result. A positive result without that context can be frightening in ways that are not helpful. A clinician who specializes in proactive brain health can help you interpret what the number actually means for you specifically.

If my result shows elevated p-tau217, what happens next?

An elevated result is a signal, not a sentence. It means the biological environment in your brain deserves closer attention and more deliberate action on the modifiable factors we know influence brain aging: sleep, cardiovascular fitness, metabolic health, inflammation, hormonal status, stress, and cognitive engagement. In some cases, additional workup may be appropriate, such as imaging or more detailed biomarker panels. The important thing is that an elevated result, found early while your cognition is intact, gives you the maximum possible runway to optimize your health in ways that may reduce risk and slow the rate of any future decline.

I carry the APOE4 gene. Does that change how I should think about this test?

Yes, it is relevant context. APOE4 is the most common genetic risk factor for late-onset Alzheimer's, and carrying it raises your background risk meaningfully. But APOE4 is not destiny: many carriers never develop dementia, and many people who do develop it do not carry the gene. What APOE4 carrier status does is make the case for proactive monitoring and early optimization even stronger. Combining genetic risk information with biomarker data gives you and your clinician a much more complete picture than either one alone, and a much stronger foundation for building a personalized plan.